The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

NCT03397888 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Portola Pharmaceuticals